{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:45:34Z","timestamp":1780418734929,"version":"3.54.1"},"reference-count":37,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To examine the clinical characteristics of patients with non-alcoholic steatohepatitis (NASH) and associated comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A case\u2013control study using the national health insurance and the long-term elderly health insurance claims database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Eligible patients diagnosed with NASH (ICD-10 K-75.8, other inflammatory liver disease or K-76.0, other fatty liver) between April 2015 and March 2020 were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Patients who met the diagnostic definitions for NASH (n=545) were matched with non-NASH controls (n=185\u2009264) and randomly selected according to sex, birth year and residential area.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>No interventions were made.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>ORs were estimated for the relationship between patient background, such as age and sex, body mass index (BMI), NASH-related comorbidities and lifestyle-related diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 545 patients with NASH (38.3% men) and 185\u2009264 non-NASH controls (43.2% men) were identified, with median ages of 68 (IQR 63.0\u201375.0) and 65 (IQR 44.0\u201374.0) years, respectively. BMI was significantly higher in patients with NASH than in controls (25.8 kg\/m<jats:sup>2<\/jats:sup>vs 22.9 kg\/m<jats:sup>2<\/jats:sup>, p&lt;0.001). The proportions of women, patients with hypertension, patients with dyslipidaemia and patients with type 2 diabetes were higher in the NASH group. In addition, NASH was associated with an increased risk of hepatic cirrhosis (OR 28.81 (95% CI 21.79 to 38.08)), followed by liver cancer (OR 18.38 (95% CI 12.56 to 26.89)). There was no significant association between NASH and risk for depression (OR 1.11 (95% CI 0.87 to 1.41)), insomnia (OR 1.12 (95% CI 0.94 to 1.34)) or chronic kidney diseases (OR 0.81 (95% CI 0.58 to 1.12)).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In the daily medical care of patients, it is necessary to consider sex and age differences and to pay close attention to the risk of liver cancer, as well as other lifestyle-related comorbidities associated with NASH.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2023-074851","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:32:51Z","timestamp":1692721971000},"page":"e074851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical characteristics in patients with non-alcoholic steatohepatitis in Japan: a case\u2013control study using a 5-year large-scale claims database"],"prefix":"10.1136","volume":"13","author":[{"given":"Kei","family":"Tokutsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-1969","authenticated-orcid":false,"given":"Kaoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"2023082209302775000_13.8.e074851.1","doi-asserted-by":"publisher","DOI":"10.1053\/J.GASTRO.2020.01.052"},{"key":"2023082209302775000_13.8.e074851.2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nanalchoholic fatty liver disease\/nonalcholic steatophepatitis 2020 (2ND edition)","volume":"56","author":"Tokushige","year":"2021","journal-title":"J Gastroenterol"},{"key":"2023082209302775000_13.8.e074851.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"2023082209302775000_13.8.e074851.4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.3"},{"key":"2023082209302775000_13.8.e074851.5","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13857"},{"key":"2023082209302775000_13.8.e074851.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"2023082209302775000_13.8.e074851.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.05.036"},{"key":"2023082209302775000_13.8.e074851.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.038"},{"key":"2023082209302775000_13.8.e074851.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.038"},{"key":"2023082209302775000_13.8.e074851.10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"56","author":"Tokushige","year":"2021","journal-title":"J Gastroenterol"},{"key":"2023082209302775000_13.8.e074851.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.014"},{"key":"2023082209302775000_13.8.e074851.12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00198-019-04844-8","article-title":"Estimates of hip fracture incidence in Japan using the national health insurance claim database in 2012-2015","volume":"30","author":"Tamaki","year":"2019","journal-title":"Osteoporos Int"},{"key":"2023082209302775000_13.8.e074851.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0533-z"},{"key":"2023082209302775000_13.8.e074851.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0311-8"},{"key":"2023082209302775000_13.8.e074851.15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-10-200511150-00009"},{"key":"2023082209302775000_13.8.e074851.16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5009\/gnl19236","article-title":"Characteristic features of nonalcoholic fatty liver disease in Japan with a focus on the roles of age, sex and body mass index","volume":"14","author":"Tobari","year":"2020","journal-title":"Gut Liver"},{"key":"2023082209302775000_13.8.e074851.17","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"2023082209302775000_13.8.e074851.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23276"},{"key":"2023082209302775000_13.8.e074851.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"2023082209302775000_13.8.e074851.20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","article-title":"Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan","volume":"56","author":"Yoneda","year":"2021","journal-title":"J Gastroenterol"},{"key":"2023082209302775000_13.8.e074851.21","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00535-021-01759-2","article-title":"Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database","volume":"56","author":"Terai","year":"2021","journal-title":"J Gastroenterol"},{"key":"2023082209302775000_13.8.e074851.22","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.3748\/wjg.v22.i16.4079","article-title":"Nonalcoholic fatty liver disease as a multi-systemic disease","volume":"22","author":"Fotbolcu","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2023082209302775000_13.8.e074851.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05640.x"},{"key":"2023082209302775000_13.8.e074851.24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00535-015-1129-1","article-title":"Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey","volume":"51","author":"Tokushige","year":"2016","journal-title":"J Gastroenterol"},{"key":"2023082209302775000_13.8.e074851.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23527"},{"key":"2023082209302775000_13.8.e074851.26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.04.034"},{"key":"2023082209302775000_13.8.e074851.27","doi-asserted-by":"crossref","unstructured":"Kimura S , Tanaka M . The relationship between non-alcoholic fatty liver disease and reflux esophagitis in Japanese subjects. Gastrointestinal Endoscopy 2007;65:AB144. doi:10.1016\/j.gie.2007.03.188","DOI":"10.1016\/j.gie.2007.03.188"},{"key":"2023082209302775000_13.8.e074851.28","doi-asserted-by":"publisher","DOI":"10.1159\/000341418"},{"key":"2023082209302775000_13.8.e074851.29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.dld.2012.08.005","article-title":"Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms","volume":"44","author":"Miele","year":"2012","journal-title":"Dig Liver Dis"},{"key":"2023082209302775000_13.8.e074851.30","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s10620-014-3113-7","article-title":"Nonalcoholic fatty liver disease increases risk for gastroesophageal reflux symptoms","volume":"59","author":"Catanzaro","year":"2014","journal-title":"Dig Dis Sci"},{"key":"2023082209302775000_13.8.e074851.31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/eci.12348","article-title":"Nonalcoholic fatty liver disease vs. obesity on the risk of erosive oesophagitis","volume":"44","author":"Hung","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"2023082209302775000_13.8.e074851.32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4103\/sjg.SJG_161_17","article-title":"Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: a meta-analysis","volume":"23","author":"Wijarnpreecha","year":"2017","journal-title":"Saudi J Gastroenterol"},{"key":"2023082209302775000_13.8.e074851.33","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/jgh.14042","article-title":"Non-alcoholic fatty liver disease and the development of reflux esophagitis: a cohort study","volume":"33","author":"Min","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2023082209302775000_13.8.e074851.34","doi-asserted-by":"crossref","unstructured":"Bang KB , Shin JE , Shin HD , et al . Sa1103 - non-obese non-alcoholic fatty liver disease is associted with erosive esophagitis. Gastroenterology 2018;154:S241. doi:10.1016\/S0016-5085(18)31184-3","DOI":"10.1016\/S0016-5085(18)31184-3"},{"key":"2023082209302775000_13.8.e074851.35","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1007\/s10620-017-4805-6","article-title":"Nonalcoholic fatty liver disease is associated with increased risk of reflux esophagitis","volume":"62","author":"Yang","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2023082209302775000_13.8.e074851.36","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.2169\/internalmedicine.54.4297","article-title":"The symptoms of gastroesophageal reflux disease correlate with high body mass index, the aspartate aminotransferase\/alanine aminotransferase ratio and insulin resistance in Japanese patients with non-alcoholic fatty liver disease","volume":"54","author":"Fujiwara","year":"2015","journal-title":"Intern Med"},{"key":"2023082209302775000_13.8.e074851.37","doi-asserted-by":"crossref","unstructured":"Xue J , Xin H , Ren N , et al . Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: a systematic review and meta-analysis. Eur J Clin Invest 2019;49:e13158. doi:10.1111\/eci.13158","DOI":"10.1111\/eci.13158"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-074851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:33:00Z","timestamp":1692721980000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-074851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,22]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjopen-2023-074851"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-074851","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}